|24th October 2020||Beth C Seidenberg||7,000||Grant/award etc.||$0.00|
|1st October 2020||Kevin T Conroy||9,391||Open or private sale||$103.57||$972,625.87|
|1st October 2020||Kevin T Conroy||5,200||Open or private sale||$104.70||$544,440.00|
|1st October 2020||Kevin T Conroy||11,698||Open or private sale||$102.86||$1,203,256.28|
|1st October 2020||Kevin T Conroy||1,136||Open or private sale||$105.20||$119,507.20|
|30th September 2020||David M Mott||1,965||Grant/award etc.||$11.93||$23,442.45|
|30th September 2020||Kevin T Conroy||933||Grant/award etc.||$11.93||$11,130.69|
|2nd September 2020||Joseph Beaulieu||543||Open or private sale||$12.88||$6,993.84|
|1st September 2020||Kevin T Conroy||19,927||Open or private sale||$75.03||$1,495,122.81|
|20th August 2020||Paolo Tombesi||2,091||Payment by withholding||$12.55||$26,242.05|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007.